SCHEMBL22789992

SCHEMBL22789992

OCc1cc2nc(Br)ccc2[nH]1

nearest known ligand 0.37

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 14/20 0.37
KDM5A P29375 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
CBFB Q13951 3/20 0.35
TDP1 Q9NUW8 1/20 0.33
ABL1 P00519 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25432411 0.86 RHEB (0.36) RHEBCBFB
SCHEMBL30552736 0.86 RHEB (0.36) RHEBCBFB
SCHEMBL22790140 0.82 DDAH1 (0.37)
SCHEMBL15750980 0.79 KDM5A (0.38) KDM5AKDM5B
SCHEMBL9396752 0.78 SIRT2 (0.41) RHEBKDM5AKDM4CKDM5BCBFB
SCHEMBL21061966 0.75 TDP1 (0.35) TDP1
SCHEMBL31609601 0.74 EGFR (0.49) KDM4CTDP1
SCHEMBL25432502 0.74 EGFR (0.49) KDM4CTDP1
SCHEMBL30552785 0.74 HSD17B10 (0.50) TDP1
SCHEMBL25432922 0.74 HSD17B10 (0.50) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4482583-B1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2026-04-01 EP disclosed
US-20250179066-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-06-05 US disclosed
EP-4482583-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2025-01-01 EP disclosed
WO-2023161316-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-31 WO disclosed
WO-2023161316-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-31 WO disclosed
US-20220306623-A1 PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-09-29 US disclosed
EP-3983409-A1 PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2022-04-20 EP disclosed
CN-114008044-A Pyridyl or pyrimidinyl MTOR kinase inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2022-02-01 CN disclosed
WO-2020249652-A1 PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179066-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS MRPL21, WIZ, CFTR RHEB 1784/4885KDM5A 3580/4885KDM4C 3991/4885
US-20220306623-A1 PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS MTOR, RICTOR, RPTOR RHEB 432/4885KDM5A 2483/4885KDM4C 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.